BROADPEAK SA: Disclosure of total number of voting rights and number of shares in the capital as of September 30, 2025

Press release – For immediate release

October 6, 2025 – 5:45 pm CEST

Disclosure of total number of voting rights and number of shares in the capital as of September 30, 2025

Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.

Sophia Antipolis, France

(*) Class E preference shares are non-voting

(**) pursuant to article 223-11 of the AMF’s General Regulations

About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit www.mediantechnologies.com.

Contacts